| Literature DB >> 9733503 |
M S Kramer1, N Cutler, J Feighner, R Shrivastava, J Carman, J J Sramek, S A Reines, G Liu, D Snavely, E Wyatt-Knowles, J J Hale, S G Mills, M MacCoss, C J Swain, T Harrison, R G Hill, F Hefti, E M Scolnick, M A Cascieri, G G Chicchi, S Sadowski, A R Williams, L Hewson, D Smith, E J Carlson, R J Hargreaves, N M Rupniak.
Abstract
The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties. Like clinically used antidepressant and anxiolytic drugs, substance P antagonists suppressed isolation-induced vocalizations in guinea pigs. In a placebo-controlled trial in patients with moderate to severe major depression, robust antidepressant effects of the substance P antagonist MK-869 were consistently observed. In preclinical studies, substance P antagonists did not interact with monoamine systems in the manner seen with established antidepressant drugs. These findings suggest that substance P may play an important role in psychiatric disorders.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9733503 DOI: 10.1126/science.281.5383.1640
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728